Abstract

The process wherein dividing cells exhaust proliferative capacity and enter into replicative senescence has become a prominent model for cellular aging in vitro. Despite decades of study, this cellular state is not fully understood in culture and even much less so during aging. Here, we revisit Leonard Hayflick’s original observation of replicative senescence in WI-38 human lung fibroblasts equipped with a battery of modern techniques including RNA-seq, single cell RNA-seq, proteomics, metabolomics, and ATAC-seq. We find evidence that the transition to a senescent state manifests early, increases gradually, and corresponds to a concomitant global increase in DNA accessibility in nucleolar and lamin associated domains. Furthermore, we demonstrate that senescent WI-38 cells acquire a striking resemblance to myofibroblasts in a process similar to the epithelial to mesenchymal transition (EMT) that is regulated by the transcription factors YAP1/TEAD1 and TGF-𝛽2. Lastly, we show that verteporfin inhibition of YAP1/TEAD1 activity in aged WI-38 cells robustly attenuates this gene expression program.

Data availability

Sequencing data have been deposited in GEO under accession code GSE175533.Proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE partner repository under accession code EBI PRIDECode for processing and analyzing data modalities have been deposited at https://github.com/dghendrickson/hayflickSource data for figures and analysis have been deposited at https://github.com/dghendrickson/hayflick and/or uploaded as source data files.

The following data sets were generated
The following previously published data sets were used

Article and author information

Author details

  1. Michelle Chan

    Calico Life Sciences, LLC, South San Francisco, United States
    Competing interests
    Michelle Chan, is affiliated with Calico Life Sciences, LLC. The author has no other competing interests to declare..
  2. Han Yuan

    Calico Life Sciences, LLC, South San Francisco, United States
    Competing interests
    Han Yuan, is affiliated with Calico Life Sciences, LLC. The author has no other competing interests to declare..
  3. Ilya Soifer

    Calico Life Sciences, LLC, South San Francisco, United States
    Competing interests
    Ilya Soifer, is affiliated with Calico Life Sciences, LLC. The author has no other competing interests to declare..
  4. Tobias M Maile

    Calico Life Sciences, LLC, South San Francisco, United States
    Competing interests
    Tobias M Maile, is affiliated with Calico Life Sciences, LLC. The author has no other competing interests to declare..
  5. Rebecca Y Wang

    Calico Life Sciences, LLC, South San Francisco, United States
    Competing interests
    Rebecca Y Wang, is affiliated with Calico Life Sciences, LLC. The author has no other competing interests to declare..
  6. Andrea Ireland

    Calico Life Sciences, LLC, South San Francisco, United States
    Competing interests
    Andrea Ireland, is affiliated with Calico Life Sciences, LLC. The author has no other competing interests to declare..
  7. Jonathon J O'Brien

    Calico Life Sciences LLC, South San Francisco, United States
    Competing interests
    Jonathon J O'Brien, is affiliated with Calico Life Sciences, LLC. The author has no other competing interests to declare..
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-9660-4797
  8. Jérôme Goudeau

    Calico Life Sciences LLC, South San Francisco, United States
    Competing interests
    Jérôme Goudeau, is affiliated with Calico Life Sciences, LLC. The author has no other competing interests to declare..
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-2483-1955
  9. Leanne JG Chan

    Calico Life Sciences LLC, South San Francisco, United States
    Competing interests
    Leanne JG Chan, is affiliated with Calico Life Sciences, LLC. The author has no other competing interests to declare.
  10. Twaritha Vijay

    Calico Life Sciences, LLC, South San Francisco, United States
    Competing interests
    Twaritha Vijay, is affiliated with Calico Life Sciences, LLC. The author has no other competing interests to declare.
  11. Adam Freund

    Calico Life Sciences, LLC, South San Francisco, United States
    Competing interests
    Adam Freund, is affiliated with Calico Life Sciences, LLC. The author has no other competing interests to declare.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-7956-5332
  12. Cynthia Kenyon

    Calico Life Sciences LLC, South San Francisco, United States
    Competing interests
    Cynthia Kenyon, is affiliated with Calico Life Sciences, LLC. The author has no other competing interests to declare.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-3446-2636
  13. Bryson D Bennett

    Calico Life Sciences, LLC, South San Francisco, United States
    Competing interests
    Bryson D Bennett, is affiliated with Calico Life Sciences, LLC. The author has no other competing interests to declare.
  14. Fiona E McAllister

    Calico Life Sciences LLC, South San Francisco, United States
    Competing interests
    Fiona E McAllister, is affiliated with Calico Life Sciences, LLC. The author has no other competing interests to declare.
  15. David R Kelley

    Calico Life Sciences, LLC, South San Francisco, United States
    Competing interests
    David R Kelley, is affiliated with Calico Life Sciences, LLC. The author has no other competing interests to declare.
  16. Margaret Roy

    Calico Life Sciences LLC, South San Francisco, United States
    Competing interests
    Margaret Roy, is affiliated with Calico Life Sciences, LLC. The author has no other competing interests to declare.
  17. Robert L Cohen

    Calico Life Sciences, LLC, South San Francisco, United States
    Competing interests
    Robert L Cohen, is affiliated with Calico Life Sciences, LLC. The author has no other competing interests to declare.
  18. Arthur D Levinson

    Calico Life Sciences, LLC, South San Francisco, United States
    Competing interests
    Arthur D Levinson, is affiliated with Calico Life Sciences, LLC. The author has no other competing interests to declare.
  19. David Botstein

    Calico Life Sciences, LLC, South San Francisco, United States
    For correspondence
    botstein@calicolabs.com
    Competing interests
    David Botstein, is affiliated with Calico Life Sciences, LLC. The author has no other competing interests to declare.
  20. David G Hendrickson

    Calico Life Sciences, LLC, South San Francisco, United States
    For correspondence
    dgh@calicolabs.com
    Competing interests
    David G Hendrickson, is affiliated with Calico Life Sciences, LLC. The author has no other competing interests to declare.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-1884-5234

Funding

The authors are employed by Calico Sciences, and no external funding was received.

Copyright

© 2022, Chan et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 9,354
    views
  • 1,353
    downloads
  • 52
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Michelle Chan
  2. Han Yuan
  3. Ilya Soifer
  4. Tobias M Maile
  5. Rebecca Y Wang
  6. Andrea Ireland
  7. Jonathon J O'Brien
  8. Jérôme Goudeau
  9. Leanne JG Chan
  10. Twaritha Vijay
  11. Adam Freund
  12. Cynthia Kenyon
  13. Bryson D Bennett
  14. Fiona E McAllister
  15. David R Kelley
  16. Margaret Roy
  17. Robert L Cohen
  18. Arthur D Levinson
  19. David Botstein
  20. David G Hendrickson
(2022)
Novel insights from a multiomics dissection of the Hayflick limit
eLife 11:e70283.
https://doi.org/10.7554/eLife.70283

Share this article

https://doi.org/10.7554/eLife.70283

Further reading

    1. Chromosomes and Gene Expression
    Felix Y Zhou, David P Waterman ... James E Haber
    Research Article

    Cells evoke the DNA damage checkpoint (DDC) to inhibit mitosis in the presence of DNA double-strand breaks (DSBs) to allow more time for DNA repair. In budding yeast, a single irreparable DSB is sufficient to activate the DDC and induce cell cycle arrest prior to anaphase for about 12–15 hr, after which cells ‘adapt’ to the damage by extinguishing the DDC and resuming the cell cycle. While activation of the DNA damage-dependent cell cycle arrest is well understood, how it is maintained remains unclear. To address this, we conditionally depleted key DDC proteins after the DDC was fully activated and monitored changes in the maintenance of cell cycle arrest. Degradation of Ddc2ATRIP, Rad9, Rad24, or Rad53CHK2 results in premature resumption of the cell cycle, indicating that these DDC factors are required both to establish and maintain the arrest. Dun1 is required for the establishment, but not the maintenance, of arrest, whereas Chk1 is required for prolonged maintenance but not for initial establishment of the mitotic arrest. When the cells are challenged with two persistent DSBs, they remain permanently arrested. This permanent arrest is initially dependent on the continuous presence of Ddc2, Rad9, and Rad53; however, after 15 hr these proteins become dispensable. Instead, the continued mitotic arrest is sustained by spindle assembly checkpoint (SAC) proteins Mad1, Mad2, and Bub2 but not by Bub2’s binding partner Bfa1. These data suggest that prolonged cell cycle arrest in response to 2 DSBs is achieved by a handoff from the DDC to specific components of the SAC. Furthermore, the establishment and maintenance of DNA damage-induced cell cycle arrest require overlapping but different sets of factors.

    1. Chromosomes and Gene Expression
    2. Developmental Biology
    Marius Regin, Yingnan Lei ... Claudia Spits
    Research Article

    About 70% of human cleavage stage embryos show chromosomal mosaicism, falling to 20% in blastocysts. Chromosomally mosaic human blastocysts can implant and lead to healthy new-borns with normal karyotypes. Studies in mouse embryos and human gastruloids showed that aneuploid cells are eliminated from the epiblast by p53-mediated apoptosis while being tolerated in the trophectoderm. These observations suggest a selective loss of aneuploid cells from human embryos, but the underlying mechanisms are not yet fully understood. Here, we investigated the cellular consequences of aneuploidy in a total of 125 human blastocysts. RNA-sequencing of trophectoderm cells showed activated p53 pathway and apoptosis proportionate to the level of chromosomal imbalance. Immunostaining corroborated that aneuploidy triggers proteotoxic stress, autophagy, p53-signaling, and apoptosis independent from DNA damage. Total cell numbers were lower in aneuploid embryos, due to a decline both in trophectoderm and in epiblast/primitive endoderm cell numbers. While lower cell numbers in trophectoderm may be attributed to apoptosis, aneuploidy impaired the second lineage segregation, particularly primitive endoderm formation. This might be reinforced by retention of NANOG. Our findings might explain why fully aneuploid embryos fail to further develop and we hypothesize that the same mechanisms lead to the removal of aneuploid cells from mosaic embryos.